Dronedarone HCl

Catalog No.S2114 Synonyms: SR33589

For research use only.

Dronedarone HCl (SR33589) is a multichannel blocker targeting potassium channel, sodium channel and calcium channel, used as an antiarrhythmic drug for treatment of atrial fibrillation (AF).

Dronedarone HCl Chemical Structure

CAS No. 141625-93-6

Selleck's Dronedarone HCl has been cited by 3 Publications

1 Customer Review

Purity & Quality Control

Choose Selective Potassium Channel Inhibitors

Other Potassium Channel Products

Biological Activity

Description Dronedarone HCl (SR33589) is a multichannel blocker targeting potassium channel, sodium channel and calcium channel, used as an antiarrhythmic drug for treatment of atrial fibrillation (AF).
Potassium channel [1] Sodium channel [1] Calcium channel [1]
In vitro

Dronedarone reduces the incidence of early and delayed after depolarizations evoked by 1 mM Dofetilide and 0.2 mM Strophantidine in Purkinje fibres. Dronedarone (10 mM) markedly reduces the L-type calcium current (76.5%) and the rapid component of the delayed rectifier potassium current (97%) in ventricular myocytes. [1] Dronedarone inhibits the activity of I(K(ACh)) channels recorded from cell-attached patches by reducing the channel open probability (from 0.56 to 0.11) without modification of the single-channel conductance in single cells isolated from sinoatrial node (SAN) tissue of rabbit hearts. [2] Dronedarone exhibits a state-dependent inhibition of the fast Na(+) channel current with an IC50 of 0.7 μM in guinea pig ventricular myocytes, when the holding potential (V (hold)) is -80 mV. Dronedarone blocks Ca(2+) currents elicited by rectangular pulses at V (hold) = -40 mV with IC50 value of 0.4 μM, whereas at V (hold) = -80 mV, Dronedarone (10 μM) blocks only 20 % of the current. [3]

In vivo Dronedarone increases action potential duration in normal hearts of rats. Dronedarone reduces the late sustained K(+) current, I(K) (or Isus) by 69%. Dronedarone induces only a tonic block of I(K). Dronedarone induces a weak increase in the fast transient outward current, I(to), in rats after myocardial infarction. [4]

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 593.22


CAS No. 141625-93-6
Storage 3 years -20°C powder
2 years -80°C in solvent

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01430806 Unknown status Drug: Dronedarone arm|Drug: Dronedarone ICD|ICD SHOCKS|DRONEDARONE Rabin Medical Center October 2011 Not Applicable
NCT01266681 Unknown status Drug: amiodarone|Drug: Dronedarone Atrial Fibrillation Eastbourne General Hospital March 2011 Not Applicable
NCT01199081 Completed Drug: Dronedarone Atrial Fibrillation Sanofi October 2010 Phase 4
NCT01213368 Completed Drug: DRONEDARONE (SR33589)|Drug: placebo Atrial Fibrillation Sanofi September 2010 Phase 2
NCT01140581 Completed Drug: DRONEDARONE Atrial Fibrillation Sanofi September 2010 Phase 4
NCT01070667 Unknown status Drug: Dronedarone|Drug: Placebo Paroxysmal Atrial Fibrillation Eastbourne General Hospital March 2010 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Dronedarone HCl | Dronedarone HCl supplier | purchase Dronedarone HCl | Dronedarone HCl cost | Dronedarone HCl manufacturer | order Dronedarone HCl | Dronedarone HCl distributor